Why a2 Milk, Air New Zealand, Mesoblast, & Recce shares are storming higher

A2 Milk Company Ltd (ASX:A2M) and Mesoblast limited (ASX:MSB) shares are two of four storming higher on Wednesday…

| More on:
share price higher

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to bounce back from yesterday’s drop. At the time of writing the benchmark index is up 0.9% to 6,658.2 points.

Four shares that are climbing more than most today are listed below. Here’s why they are storming higher:

A2 Milk Company Ltd (ASX: A2M)

The a2 Milk share price is up a further 3.5% to $11.15. Investors have been buying the infant formula company’s shares this week after a horror showing a week earlier. It appears as though some investors believe the sell off on Friday has dragged its shares down to an attractive level. The a2 Milk share price was sold off after it downgraded its guidance for FY 2021.

Air New Zealand Limited (ASX: AIZ)

The Air New Zealand share price is up 3.5% to $1.64. This follows the release of an update on its operations this morning. Air New Zealand revealed that it carried a total of 690,000 passengers in November. While this is roughly half what it carried a year earlier, it is an improvement from earlier in the financial year.

Mesoblast limited (ASX: MSB)

The Mesoblast share price is up 6% to $2.30 despite there being no news out of the biotech company. However, with its shares halving in value over the last few trading days, some investors may believe they have been oversold. Alternatively, as Mesoblast is one of the most shorted shares on the ASX, the buying could be from short sellers closing positions.

Recce Pharmaceuticals Ltd (ASX: RCE)

The Recce share price has pushed 4% higher to $1.12. The catalyst for this was the release of results from its international SARS-CoV-2 (COVID-19) in-vivo studies. The results demonstrate positive activity of RECCE 327 (R327) and RECCE 529 (R529) against COVID-19 in Syrian golden hamsters. Management believes this hamster study is the first indication of the potential for nasal administration of its anti-infective compounds, specifically when used against viruses.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers